Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women aged 18-48 inclusive~* Endometriosis documented by laparoscopic or surgical assessment within the past ten (10) years~* Clinical symptoms of endometriosis for at least the past three (3) months~* Endometriosis symptoms~* Must be sexually active unless sexually inactive for endometriosis-related dyspareunia~* Must have a regular or steady menstrual cycle lasting from 24 to 36 days and a detectable ovulation during the baseline period using an ovulation monitoring kit (for timing of endometrial biopsy)~* Other inclusion criteria may apply~Exclusion Criteria:~* Six (6) months or more without a menstrual period, or~* Prior hysterectomy or~* Prior bilateral oophorectomy~* Diagnosis of osteopenia~* Present history or condition that causes non-endometriosis-related dyspareunia~* Presence of excessive bleeding or menorrhagia~* Abnormal screening endometrial biopsy~* Other exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily
- 25 mg (Type: EXPERIMENTAL): Proellex 25 mg once daily
- 50 mg (Type: EXPERIMENTAL): Proellex 50 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).